Welcome to our dedicated page for Quantum Biopharma Ltd. Class B Subordinate Voting Shares news (Ticker: QNTM), a resource for investors and traders seeking the latest updates and insights on Quantum Biopharma Ltd. Class B Subordinate Voting Shares stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Quantum Biopharma Ltd. Class B Subordinate Voting Shares's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Quantum Biopharma Ltd. Class B Subordinate Voting Shares's position in the market.
Quantum BioPharma (NASDAQ:QNTM) announced upcoming court proceedings against former CEO Dr. Raza Bokhari on January 24, 2025, seeking to declare him a vexatious litigant. The company has previously won multiple legal battles against Bokhari, who was terminated for cause in July 2021, resulting in approximately $3 million in awards in favor of Quantum BioPharma.
An arbitrator dismissed Bokhari's wrongful dismissal claim and awarded the company CDN$2.81 million plus interest. Additional court costs awarded include $175,000 from Justice Conway and $5,000 from the Court of Appeal. The U.S. District Court granted judgment in favor of Quantum BioPharma, including various monetary awards with interest rates ranging from 4% to 6%. Bokhari has appealed this judgment and provided a supersedeas bond for USD $2,882,441.48 pending the United States Court of Appeals decision.
Quantum BioPharma (NASDAQ:QNTM) announces its dual listing on Upstream, a MERJ Exchange market and global securities trading app, starting January 14, 2025, at 10:00am EST. The company, focused on developing treatments for neurodegenerative, metabolic, and alcohol misuse disorders, will maintain its listings on Nasdaq, Canadian Securities Exchange, and Frankfurt exchanges.
The Upstream platform operates 20 hours daily, offering real-time trading and settlement with transparent orderbook features. Non-U.S. investors can access QNTM shares through the Upstream app after completing KYC verification. Trading will begin once an existing shareholder places a sale offer.
CEO Zeeshan Saeed states this dual listing aims to add value and liquidity while expanding their reach to a global investor base. U.S. persons are restricted from depositing, buying, or selling securities on Upstream.
Quantum BioPharma (NASDAQ:QNTM) has received approval for dual listing on Upstream, a MERJ Exchange market and global securities trading app. Trading will commence on January 14, 2025, at 10:00am ET under the ticker 'QNTM'. The dual listing aims to provide access to a global investor base outside the U.S., enabling trading through various payment methods including credit/debit cards, PayPal, USD, or USDC.
The Upstream platform operates 20 hours daily, 7 days a week, featuring real-time trading and settlement with a transparent orderbook designed to prevent market manipulation. Non-U.S. investors can participate by downloading the Upstream app, completing KYC verification, and following specific share transfer procedures.
The company, which focuses on developing treatments for neurodegenerative and metabolic disorders, views this dual listing as a strategic move to enhance shareholder value by increasing liquidity and improving price discovery.
Quantum BioPharma (NASDAQ:QNTM) has announced the closing of a second tranche of its previously announced offering from December 5, 2024. The company has issued 500 Debenture Units for $500,000. The proceeds will be allocated to the ongoing development of the company's business model and general working capital purposes. All securities issued in this second tranche are subject to a four-month and one-day statutory hold period from the issuance date. The securities are not registered under the U.S. Securities Act and cannot be offered or sold in the United States without registration or an applicable exemption.
Quantum BioPharma (NASDAQ:QNTM) has announced a strategic investment of USD $1,000,000 in Bitcoin (BTC) and other cryptocurrencies following Board approval. The company will also accept cryptocurrency for future financings and transactions, storing all digital assets with a compliant custodian.
CEO Zeeshan Saeed cited Bitcoin's increased legal and market legitimacy, including the emergence of BTC-based ETFs and anticipated pro-crypto policies, as key factors in this decision. The company maintains flexibility to adjust its cryptocurrency holdings based on market conditions, viewing this investment as an opportunity to grow non-operational capital while aligning with emerging financial trends.
Quantum BioPharma (NASDAQ: QNTM) has announced a strategic investment of USD $1,000,000 in Bitcoin (BTC) and other cryptocurrencies following Board approval. The company will now accept cryptocurrency for future financings and other transactions, working with a fully compliant custodian.
CEO Zeeshan Saeed stated this move aims to grow non-operational capital, citing Bitcoin's increasing legal and market legitimacy, including the emergence of BTC-based ETFs and anticipated pro-crypto policies. The company maintains flexibility to adjust its cryptocurrency holdings based on market conditions, emphasizing full compliance with financial and audit regulations.
Quantum BioPharma (NASDAQ/CSE/FRA: QNTM) has announced the closing of the first tranche of its previously announced offering from December 5, 2024. The company has issued 500 Debenture Units raising CAD $500,000. The proceeds will be allocated to the company's ongoing business model development and general working capital. Securities issued in this tranche are subject to a four-month and one-day statutory hold period from issuance. The company's obligations under the Debentures are no longer collaterally secured by general security.
Quantum BioPharma (NASDAQ: QNTM) announced that the safety review committee has recommended proceeding with the second cohort dosing in their Phase 1 Multiple Ascending Dose clinical trial for Lucid-21-302. The trial, conducted through subsidiary HUGE Biopharma Australia, is evaluating safety and pharmacokinetics of Lucid-21-302 in healthy adult participants. The recommendation follows a review of safety and pharmacokinetic data from the first cohort. The second cohort dosing is expected to begin within days.
Quantum BioPharma (NASDAQ:QNTM) has announced a non-brokered private placement offering of up to 5,000 convertible debenture units at $1,000 per unit, aiming to raise up to $5 million. Each unit includes a $1,000 secured convertible debenture and 80 class B share purchase warrants.
The debentures will mature in 36 months with a 1.25% monthly interest rate, payable quarterly. They are convertible into class B shares at $6.25 per share. The warrants allow holders to purchase additional class B shares at $7.00 per share within 5 years. The proceeds will support business development and working capital. The company also settled $43,825.17 in debt through the issuance of 7,500 shares at $5.84 per share.
Quantum BioPharma (NASDAQ:QNTM), formerly FSD Pharma, has filed a US$700M+ lawsuit against CIBC World Markets, RBC Dominion Securities and others for alleged market manipulation and share price spoofing. The company has assembled legal teams working on a contingency basis, meaning no upfront costs for the company.
The company is actively inviting shareholders who experienced losses during the relevant period to join the case by sharing details of their trading losses and personal impact. Information can be submitted via email or through the company's website on the 'Quantum vs Banks' page, which will be updated periodically with case progress.
FAQ
What is the current stock price of Quantum Biopharma Ltd. Class B Subordinate Voting Shares (QNTM)?
What is the market cap of Quantum Biopharma Ltd. Class B Subordinate Voting Shares (QNTM)?
